|
Malignant neoplasm of breast
|
0.310 |
Biomarker
|
disease |
BEFREE |
Thus, we identified RSPO3 as a novel key modulator of breast cancer development and a potential target for treatment of basal-like breast cancers.<b>Significance:</b> These findings identify RSPO3 as a potential therapetuic target in basal-like breast cancers.<b>Graphical Abstract:</b> http://cancerres.aacrjournals.org/content/canres/78/16/4497/F1.large.jpg <i></i>.
|
29748375 |
2018 |
|
Breast Carcinoma
|
0.310 |
Biomarker
|
disease |
BEFREE |
Thus, we identified RSPO3 as a novel key modulator of breast cancer development and a potential target for treatment of basal-like breast cancers.<b>Significance:</b> These findings identify RSPO3 as a potential therapetuic target in basal-like breast cancers.<b>Graphical Abstract:</b> http://cancerres.aacrjournals.org/content/canres/78/16/4497/F1.large.jpg <i></i>.
|
29748375 |
2018 |
|
Crohn Disease
|
0.110 |
Biomarker
|
disease |
BEFREE |
We previously reported that Rspo2 is a major determinant of susceptibility to Citrobacter rodentium-mediated colitis in mice and recent genome-wide association studies have revealed RSPO3 as a candidate Crohn's disease-specific inflammatory bowel disease susceptibility gene in humans.
|
27046199 |
2016 |
|
Neoplasms
|
0.070 |
Biomarker
|
group |
BEFREE |
RSPO3 knockdown in basal-like mouse mammary tumor cells reduced canonical Wnt signaling, epithelial-to-mesenchymal transition-like features, migration capacity, and tumor formation <i>in vivo</i> Conversely, RSPO3 overexpression, which was associated with some LGR and RUNX factors, highly correlated with the basal-like subtype among patients with breast cancer.
|
29748375 |
2018 |
|
Neoplasms
|
0.070 |
AlteredExpression
|
group |
BEFREE |
Meanwhile, RSPO3 overexpression promoted tumor growth both <i>in vivo</i> and <i>in vitro</i>.
|
31851527 |
2020 |
|
Neoplasms
|
0.070 |
Biomarker
|
group |
BEFREE |
Aberrant RSPO3-LGR4 signaling in Keap1-deficient lung adenocarcinomas promotes tumor aggressiveness.
|
25531322 |
2015 |
|
Neoplasms
|
0.070 |
Biomarker
|
group |
BEFREE |
Involvement of RSPO3 in tumour growth was recently shown in <i>RSPO3</i>-fusion-positive xenograft models.
|
27511199 |
2017 |
|
Neoplasms
|
0.070 |
GeneticVariation
|
group |
BEFREE |
Altogether, our study provides direct evidence that endogenous Rspo2 and Rspo3 chromosome rearrangements can initiate and maintain tumour development, and indicate a viable therapeutic window for LGK974 treatment of RSPO-fusion cancers.
|
28695896 |
2017 |
|
Neoplasms
|
0.070 |
AlteredExpression
|
group |
BEFREE |
This binding upregulates Rspo3 oncogene expression and downregulates GJA1 tumor suppressor gene expression in a Foxp3-dependent manner.
|
26735887 |
2016 |
|
Neoplasms
|
0.070 |
Biomarker
|
group |
BEFREE |
In these latter types of tumors that represent over 90% of CRC, RSPO3 is produced by stromal cells in the tumor microenvironment and the activating mutations appear to sensitize the tumors to Wnt-Rspo synergy.
|
29127379 |
2017 |
|
Colorectal Carcinoma
|
0.050 |
Biomarker
|
disease |
BEFREE |
Recurrent, gain-of-expression gene fusions of RSPO2 (to EIF3E) and RSPO3 (to PTPRK) occur in a subset of human colorectal cancer.
|
25531322 |
2015 |
|
Colorectal Carcinoma
|
0.050 |
GeneticVariation
|
disease |
BEFREE |
In this study, we examined 75 primary CRCs and 121 primary lung cancers in the Japanese population for EIF3E-RSPO2 and PTPRK-RSPO3 fusion transcripts using RT-PCR and subsequent sequencing analyses.
|
24847761 |
2014 |
|
Colorectal Carcinoma
|
0.050 |
Biomarker
|
disease |
BEFREE |
This establishes RSPO3 as a potent driver of intestinal cancer and proposes RSPO3 as a candidate target for therapy in patients with colorectal cancer harbouring <i>RSPO3</i> fusions.
|
27511199 |
2017 |
|
Colorectal Carcinoma
|
0.050 |
AlteredExpression
|
disease |
BEFREE |
Using a pipeline designed to suppress stroma-derived signal, we find that RSPO3 "outlier" expression in CRC samples highlights translocation and fusion transcript expression.
|
28100566 |
2017 |
|
Colorectal Carcinoma
|
0.050 |
Biomarker
|
disease |
BEFREE |
Here we show that RSPO3 antagonism synergizes with paclitaxel based chemotherapies in patient-derived xenograft models (PDX) with RSPO3 fusions and in tumors with common CRC mutations such as APC, β-catenin, or RNF43.
|
29127379 |
2017 |
|
Malignant neoplasm of lung
|
0.040 |
Biomarker
|
disease |
BEFREE |
Knockdown (KD) of RSPO3, LGR4 or their signaling mediator IQGAP1 in lung cancer cell lines with Keap1 deficiency and high RSPO3-LGR4 expression led to reduction in cell proliferation and migration in vitro, and KD of LGR4 or IQGAP1 resulted in decrease in tumor growth and metastasis in vivo.
|
25531322 |
2015 |
|
Malignant neoplasm of lung
|
0.040 |
Biomarker
|
disease |
BEFREE |
R-Spondin 3 (RSPO3) is a protein previously implicated in the progression of colorectal and lung cancers.
|
30987640 |
2019 |
|
Malignant neoplasm of lung
|
0.040 |
Biomarker
|
disease |
BEFREE |
These results suggest that RSPO1, RSPO2 and RSPO3 may serve as distinct biomarkers and prognostic factors in patients with lung cancer.
|
31579414 |
2019 |
|
Malignant neoplasm of lung
|
0.040 |
GeneticVariation
|
disease |
BEFREE |
In this study, we examined 75 primary CRCs and 121 primary lung cancers in the Japanese population for EIF3E-RSPO2 and PTPRK-RSPO3 fusion transcripts using RT-PCR and subsequent sequencing analyses.
|
24847761 |
2014 |
|
Malignant Neoplasms
|
0.020 |
Biomarker
|
group |
BEFREE |
Thus, we identified RSPO3 as a novel key modulator of breast cancer development and a potential target for treatment of basal-like breast cancers.<b>Significance:</b> These findings identify RSPO3 as a potential therapetuic target in basal-like breast cancers.<b>Graphical Abstract:</b> http://cancerres.aacrjournals.org/content/canres/78/16/4497/F1.large.jpg <i>Cancer Res; 78(16); 4497-511.©2018 AACR</i>.
|
29748375 |
2018 |
|
Malignant Neoplasms
|
0.020 |
GeneticVariation
|
group |
BEFREE |
Consistent with a central role of Wnt signaling in regulation of gene expression, inhibition of PORCN in RSPO3-translocated cancers causes a marked remodeling of the transcriptome, with loss of cell cycle, stem cell and proliferation genes, and an increase in differentiation markers.
|
26257057 |
2016 |
|
Neoplasm Metastasis
|
0.020 |
AlteredExpression
|
phenotype |
BEFREE |
RSPO3 levels are lower in prostate cancer than normal prostate, with a tendency for further loss in metastatic disease.
|
30987640 |
2019 |
|
Neoplasm Metastasis
|
0.020 |
AlteredExpression
|
phenotype |
BEFREE |
Knockdown (KD) of RSPO3, LGR4 or their signaling mediator IQGAP1 in lung cancer cell lines with Keap1 deficiency and high RSPO3-LGR4 expression led to reduction in cell proliferation and migration in vitro, and KD of LGR4 or IQGAP1 resulted in decrease in tumor growth and metastasis in vivo.
|
25531322 |
2015 |
|
Adenocarcinoma of lung (disorder)
|
0.020 |
Biomarker
|
disease |
BEFREE |
In the survival analysis, increased mRNA expression levels of RSPO1, RSPO2 and RSPO3 were associated with increased survival in patients with lung adenocarcinomas.
|
31579414 |
2019 |
|
Adenocarcinoma of lung (disorder)
|
0.020 |
Biomarker
|
disease |
BEFREE |
These findings suggest that aberrant RSPO3-LGR4 signaling potentially acts as a driving mechanism in the aggressiveness of Keap1-deficient lung ADs.
|
25531322 |
2015 |